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A cross-sectional survey of potential factors,
motivations, and barriers influencing
research participation and retention among
people who use drugs in the rural USA
Angela T. Hetrick1* , April M. Young2,3, Miriam R. Elman4, Sarann Bielavitz4,5, Rhonda L. Alexander2,
Morgan Brown1, Elizabeth Needham Waddell4,5, P. Todd Korthuis4,5 and Kathryn E. Lancaster1
Abstract
Background: Despite high morbidity and mortality among people who use drugs (PWUD) in rural America, most
research is conducted within urban areas. Our objective was to describe influencing factors, motivations, and
barriers to research participation and retention among rural PWUD.
Methods: We recruited 255 eligible participants from community outreach and community-based, epidemiologic
research cohorts from April to July 2019 to participate in a cross-sectional survey. Eligible participants reported opioid
or injection drug use to get high within 30 days and resided in high-needs rural counties in Oregon, Kentucky, and
Ohio. We aggregated response rankings to identify salient influences, motivations, and barriers. We estimated
prevalence ratios to assess for gender, preferred drug use, and geographic differences using log-binomial models.
Results: Most participants were male (55%) and preferred methamphetamine (36%) over heroin (35%). Participants
reported confidentiality, amount of financial compensation, and time required as primary influential factors for research
participation. Primary motivations for participation include financial compensation, free HIV/HCV testing, and
contribution to research. Changed or false participant contact information and transportation are principal barriers to
retention. Respondents who prefer methamphetamines over heroin reported being influenced by the purpose and use
of their information (PR = 1.12; 95% CI: 1.00, 1.26). Females and Oregonians (versus Appalachians) reported knowing
and wanting to help the research team as participation motivation (PR = 1.57; 95% CI: 1.09, 2.26 and PR = 2.12; 95% CI:
1.51, 2.99).
Conclusions: Beyond financial compensation, researchers should emphasize confidentiality, offer testing and linkage
with care, use several contact methods, aid transportation, and accommodate demographic differences to improve
research participation and retention among rural PWUD.
Keywords: Rural, Substance use, Recruitment, Opioid, Injection drug use, Participant retention
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Introduction
The rural United States (U.S.) is in the midst of an on-
going substance use disorder epidemic. In 2019, one in
five Americans used an illicit drug and 70,630 drug over-
dose deaths occurred in the U.S, of which 71% were
opioid-related [1, 2]. Further exacerbating the substance
use epidemic is the prediction of the opioid epidemic’s
“4th wave” or the rise in methamphetamine use among
people with opioid use disorders [3–6]. People who use
drugs (PWUD) such as opioids and methamphetamines
face rising rates of HCV, HIV, and other chronic health
conditions [7–9]. When rural PWUD attempt to access
treatment for these health conditions, they face trans-
portation barriers, stigma from healthcare providers, and
a shortage of providers who offer care for substance use
disorders (SUD) and their associated harms (e.g., HCV
and HIV) [8, 10–12].
Despite high morbidity and mortality among PWUD
in rural America, most clinical research is conducted
among urban residents [13]. Results from clinical studies
may not always translate to rural communities because
of the various demographic, sociocultural, and infra-
structural differences [14–17]. PWUD in rural commu-
nities may benefit from participation in research through
otherwise unavailable access to SUD knowledge, special-
ists, and medical facilities, the receipt of new and effect-
ive treatments and medical care, and supported linkage
to community SUD resources and programs [18, 19]. Al-
though research studies such as clinical trials may pro-
vide valuable care and treatment to rural PWUD,
retention and recruitment remains challenging [15, 20,
21]. Those in rural communities note mistrust and fear
as contributors to low recruitment, and rural residents
have a lower likelihood of awareness of opportunities to
participate in research compared to their urban counter-
parts [21, 22].
Factors affecting clinical trial recruitment and reten-
tion can be categorized using the Ickovics and Mieslers
multifactorial framework: the individual, treatment regi-
men, patient-provider relationship, clinical setting, and
the disease [23]. There is mixed evidence for the pres-
ence of individual level differences in research enroll-
ment and retention between genders. The National
Institute on Drug Abuse (NIDA) Treatment Clinical Tri-
als Network (CTN) did not identify proportional differ-
ences in enrollment and retention between genders, and
willingness to participate in an HCV vaccine trial among
PWUD did not differ by gender [24–26]. However, other
studies suggest that women are underrepresented in
HCV and HIV clinical research [27], and gender differ-
ences in utilization of harm reduction services exist
among rural PWUD [28]. Further, there is some evi-
dence to indicate that considerations for participating in
research studies differ by gender [29, 30]. An individual’s
drug preference for methamphetamine over heroin may
also impact trust in research due to adverse effects such
as elevated paranoia and suspiciousness associated with
methamphetamine use [31]. Patient-provider relation-
ship factors such as stigmatizing attitudes unique to cer-
tain drugs [32–34] could result in variations in the
perceived judgment by staff as a factor affecting partici-
pation in research studies, including studies irrelevant to
substance use.
Our study’s primary objective is to describe the influ-
encing factors, motivations, and barriers of rural PWUD
in participation and retention in research studies. The
study’s secondary objective is to examine variation in in-
fluencing factors, motivations, and barriers across geo-
graphic regions, gender, and substance use to inform
retention and recruitment strategies.
Methods
Study setting
We conducted a cross-sectional survey from April to
July 2019 in rural areas of Kentucky, Ohio, and Oregon,
where each state has an established research infrastruc-
ture through the National Rural Opioid Initiative [35].
Rural study sites in Eastern Kentucky and Southeastern
Ohio are located in Appalachia, a cultural and geograph-
ical region that spans 13 states from New York to Mis-
sissippi [36]. The Oregon rural study sites in the Pacific
Northwest include both coastal and interior communi-
ties in large, sparsely populated counties. The popula-
tions in these areas of Appalachia and Oregon are
predominantly White, and an estimated 12–38% of the
population lives below the poverty line, compared to the
U.S. national average of 10.5% [37, 38]. These rural com-
munities are at increased vulnerability for HIV and HCV
transmission due to high injection drug use rates and in-
adequate healthcare infrastructures [39–41].
Study design
The cross-sectional, multi-state survey was part of the
formative phase of the Peer-based Retention of People
who Use Drugs in Rural Research (PROUD-R2) study
that tests rural peers’ ability to improve study retention
(ClinicalTrials.gov identifier: NCT03885024) [42]. We
estimated that a sample size of 225 participants, or ap-
proximately 75 participants per site, would provide a sat-
uration of responses to inform the central phase of
PROUD-R2.
Eligible participants were at least 18 years of age,
injected any drug or used opioids through non-injection
methods (such as smoking, inhaling, snorting, or swallow-
ing) to get high within the past 30 days, and lived within
rural counties associated with each study site. We re-
cruited participants using convenience sampling at syringe
service programs, local health departments, community-
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based settings, and through concurrent epidemiologic
studies. We obtained informed consent from all partici-
pants and provided each participant with $20 cash or a gift
card as reimbursement for survey participation. The sur-
vey was interviewer-administered in Kentucky and Ore-
gon and self-administered in Ohio. In Ohio, trained study
staff followed an IRB-approved script to recruit and ver-
bally determine participant eligibility as persons departed
a local, weekly syringe service program. In Kentucky, indi-
viduals who had participated in a previous study on drug
use in the study region and who had consented to be con-
tacted about future research opportunities were contacted
by the study staff and invited to participate using an IRB-
approved recruitment script. To those who were inter-
ested in participating, staff verbally administered each
question from the eligibility screening survey and re-
corded their responses in the survey instrument. In some
cases, individuals who were screened and/or enrolled in-
formally told their peers about the study who then called
to express interest in participating and were screened. In
Oregon, potential participants were recruited from syringe
service programs through flyers and staff and peer refer-
rals. Survey instruments were administered and responses
electronically recorded by research staff, as in Kentucky.
We used self-administration survey methods in Ohio to
ensure confidentiality of participant responses as data col-
lection occurred in a shared room of a local syringe ser-
vice program. In Kentucky and Ohio, we collected data
using Qualtrics software, Version June 2019 (Qualtrics,
Provo, UT). In Oregon, study data were collected using
REDCap electronic data capture tools hosted at Oregon
Health & Science University [Grant#: UL1TR002369 ][43].
Data collection
We constructed our survey based on prior literature on
clinical trial participation among PWUD and adapted
from previous assessments of vaccine trial willingness
[24, 44, 45]. Questions were adapted to ask without ref-
erence to a specific vaccine or trial product to more
broadly understand factors, motivations, and barriers to
research participation and retention among rural
PWUD. The Community Advisory Board of the Ken-
tucky CARE2HOPE study and peer recovery support
specialists of the Oregon OR-HOPE study reviewed and
approved the survey’s final version to confirm the appro-
priateness of the survey.
Participants provided the following demographic infor-
mation: age, gender, education, race, and ethnicity. We
assessed gender using the construct, “What is your gen-
der?” in alignment with recommendations to use gender
as opposed to sex when reporting psychosocial or cul-
tural factors [46]. We also asked participants about re-
cent drug use, “Have you ever injected drugs to get
high?”, “Which drugs have you injected in the past 30
days to get high?”, and “Which is your drug of choice for
getting high?”.
To capture each participant’s history with research
studies, we asked, “Before today, have you ever partici-
pated in a research study?” Participants who selected
“yes” were prompted to select all that apply to, “What
did the research you participated in involve?” Response
options included “in-person survey(s) or interview(s),”
“telephone survey(s),” “testing for a disease or health
condition (not including a urine drug test),” “a clinical
trial testing a new drug, treatment or device,” “follow-up
appointments for surveys and/or testing,” “financial in-
centive (i.e., money or gift card given for participation),”
and “other (please specify).”
We collected data on (1) influencing factors for re-
search participation, (2) motivations for participating in
research, and (3) barriers to attend follow-up research
appointments through a series of nominal response op-
tion questions in which the participant could “select all
that apply.” To elicit factors that influenced participants’
decision to participate in a research study, we asked,
“What are some of the things that people who use drugs
in this community may consider when deciding to par-
ticipate in a research study?” [15 response options]. We
inquired, “What are some of the reasons that people
who use drugs in this community may decide to partici-
pate in a research study?” [10 response options] to ob-
tain their motivations for participation in research. To
assess barriers to retention in attending follow-up re-
search appointments, we asked, “What do you think are
some of the challenges to getting people to come back
for follow-up appointments?” [11 response options].
Each question included an “other” response option that,
if selected, prompted participants to specify a response
not listed. Complete response options for all three ques-
tions are listed in Tables 3, 4, and 5. If a participant se-
lected more than three responses to the above questions,
they were prompted to “Select their top 3” options by
specifying their “1st choice,” 2nd choice,” and “3rd
choice” from their previously selected responses, here-
after referred to as primary, secondary, and tertiary re-
sponses. Their remaining selected responses were
categorized as “unranked.” For participants that selected
a single response, we categorized the response as “pri-
mary.” For participants that selected only two to three
responses we categorized their responses as “top three,
unranked.” If a participant ranked only one to two re-
sponses, the remaining responses were categorized as
“unranked.”
Statistical analyses
Participant sociodemographics and drug use characteris-
tics were summarized using descriptive statistics. We ex-
cluded participants from analyses if they were missing a
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response for one or more of the eligibility questions. To
visually represent and compare the ranking of partici-
pant responses, we used diverging stacked bar charts
[47]. We displayed survey items with the highest to low-
est frequency of primary, secondary, and tertiary re-
sponses. We also included counts of selected, but
unranked, responses for each survey item.
We aggregated the survey responses into 36 binary
dependent variables to analyze the differences of influen-
cing factors, motivations for participation, and barriers
to retention in research among subgroups of the study
population. Due to small cell sizes, we condensed the
rankings of each response into dichotomous variables
(“selected,” “not selected”) that represented a partici-
pant’s response to selecting items as essential influencing
factors, motivations, or barriers.
Of the demographic variables available, we selected
and dichotomized three variables a priori with the po-
tential to inform future research recruitment and reten-
tion protocols. Specifically, we conducted comparisons
by gender given mixed findings from previous research
on the association between gender and reasons for re-
search participation [29, 30]. Analyses by geographic lo-
cation and type of drug use address gaps in the literature
on how these factors may impact research participation.
The latter is especially important given the evolving drug
epidemic in rural areas from one that is predominated
by opioids to one of polysubstance use involving meth-
amphetamine [48]. We assessed differences in the
dependent variable by the independent variables of gen-
der (male, female), region (Appalachia, Oregon), and
preferred drug of choice (heroin, methamphetamine).
We combined Kentucky and Ohio into a single “Appala-
chia” group for several conceptual and statistical reasons:
the stratified prevalence ratios of Kentucky and Ohio
were similar when compared to Oregon, the Kentucky
and Ohio research sites are geographically close, and
both are in the Appalachian region. Of the preferred
choice of drug options included in our survey, we com-
pared heroin and methamphetamine as most partici-
pants selected one or the other as their ideal drug of
choice. To ensure that “preferred drug of choice”
reflected actual use, we verified that most participants
had access to their preferred drug of choice by generat-
ing cross tabulations with their preferred drug of choice
and reported substance use in the past 30 days.
We selected log-binomial regression a priori to assess
differences in site, gender, and preferred drug use for
each of the 36 selected responses. Prevalence ratios (PR)
and corresponding 95% confidence intervals (CI) were
estimated for each bivariable model. To reduce bias and
improve model precision, only survey items with at least
ten responses at each level of the binary dependent vari-
able were modeled [49–51].
We aggregated and analyzed data using SAS software
version 9.4 (SAS Institute Inc., Cary, NC) at Oregon
Health and Science University and the Ohio State Uni-
versity. Plots were developed with the “HH” package in
R version 4.0.2 (R Core Team, Vienna, Austria )[52, 53].
The Ohio State University Institutional Review Board,
University of Kentucky Institutional Review Board, and
Oregon Health and Science University Institutional Re-
view Board approved this study.
Results
Participant characteristics
A total of 290 participants completed the survey. In Ore-
gon and Kentucky, a total of 218 participants were
screened and completed the survey, and 34 participants
were ineligible, for reasons including not meeting drug
use eligibility criteria (n = 28), living outside of the study
location (n = 4), or missing information for all eligibility
criteria (n = 2). In Ohio, a total of 72 participants were
screened and completed the survey. Participant eligibility
was assessed verbally using a recruitment and eligibility
script, and the number of ineligible participants and rea-
sons for ineligibility were not recorded. Furthermore,
one Ohio participant was excluded from the analyses
due to missing age and could not be confirmed to meet
study eligibility. The final analytic sample contained 255
participants and included a complete set of responses
for all independent and dependent variables.
The characteristics of the 255 participants included in
our study are shown in Table 1. Most participants were
from Kentucky (n = 105), then Oregon (n = 79),
followed by Ohio (n = 71), and the median participant
age was 37 years (IQR: (30, 45); range: (19, 72)). Most
participants identified as male (55%), white (88%), and
had at least a high school diploma/General Educational
Development (GED) (73%). One participant identified
their gender as “Transgender” and another participant
identified as “Unknown/Unsure.” We excluded these
participants from the analysis between gender differ-
ences to avoid applying unreliable findings to these sub-
populations resulting from their small sample sizes.
Further, if these two individuals were described in more
detail demographically and behaviorally, they may be
identifiable in their communities, and we wish to protect
their confidentiality.
Nearly all participants had a lifetime history of
injecting drugs to get high (93%) (Table 2). Most
participants preferred either heroin or methampheta-
mine; both groups reported recent use (92% for her-
oin, 95% for methamphetamine), and both were the
most commonly injected drugs in the past 30 days
(57% and 61%, respectively). Other recently injected
drugs included fentanyl (18%), buprenorphine (18%),
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painkillers (15%), cocaine/crack (8%), methadone (3%),
and prescription anxiety drugs (3%).
Most participants had previously participated in a research
study (64%). The most commonly reported types of research
were “in-person survey or interview” (n = 152), research that
included a financial incentive (n = 120), research testing for a
disease or health condition (n = 110), and research with
follow-up appointments for a survey/testing (n = 92). Few
participants noted research experience with telephone sur-
veys (n = 6), clinical trials (n = 5), and other (n = 6). Partici-
pants who selected “other” reported participating in a
research study that included, “drug swa(b) test,” “filling out
papers,” “Narcan,” “computer surveys,” “internet surveys,”
and one participant left their response blank.
Patterns of influencing factors in decision to participate
in research studies
The primary influencing factor for research participation
was the amount of financial compensation received in
exchange for participation (Fig. 1), followed by confiden-
tiality of information. Other essential influencing factors
among rural PWUD were the time required to partici-
pate in the research study and privacy of the research of-
fice. The influencing factor with the least number of
ranked responses was whether the research institution
or university was well-respected. Five participants se-
lected “other” as an influencing factor for research par-
ticipation. “Other” responses included “how much [the
study] would help the community,” “whose approaching
Table 1 Demographics of PWUD who completed a cross-sectional survey in rural Oregon, Ohio, and Kentucky, April–July 2019
Total study population Oregon Kentucky Ohio
(n = 255) (n = 79) (n = 105) (n = 71)
n % n % n % n %
Age
Median (IQR) 37 (30, 45) 34 (29, 43) 37 (30, 45) 38 (32, 45)
(Range) (19, 72) (19, 61) (19, 72) (25, 66)
Gender
Female 116 45 36 46 51 49 29 41
Male 137 55 43 54 54 51 40 56
Transgender 1 0 0 0 0 0 1 1
Unknown/unsure 1 0 0 0 0 0 1 1
Race
White 225 88 60 76 104 99 61 86
Black/African American 5 2 2 3 0 0 3 4
American Indian/Alaskan
Native
6 2 5 6 0 0 1 1
Mixed race 13 5 10 13 1 1 2 3
Other 6 2 2 3 0 0 4 6
Ethnicity
Hispanic 14 5 11 14 1 1 2 3
Non-Hispanic 241 95 68 86 104 99 69 97
Education
Less than high school 69 27 10 13 41 39 18 25
High school diploma or GED 106 42 36 46 40 38 30 42
Some college 59 23 29 37 19 18 11 16
Associate’s degree, trade, or technical college 16 6 3 4 4 4 9 13
Bachelor’s degree or higher 3 1 1 1 1 1 1 1
Missing 0 0 0 0 0 0 2 3
Highest level of education
High school diploma or GED 184 73 69 87 64 61 51 74
Below high school diploma or GED 69 27 10 13 41 39 18 25
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them and how they are approached,” and two responses
were left blank.
In considering participation in research, Oregon respon-
dents had a higher prevalence of selecting all influencing
factors listed compared to Appalachian respondents.
When compared to Appalachian respondents, Oregon re-
spondents were more influenced by how much time is re-
quired for participation (PR = 1.42; 95% CI: 1.21, 1.67)
and the frequency of research appointments (Oregon
prevalence: 87%, Appalachian prevalence: 41%, PR = 2.14;
95% CI: 1.75, 2.60). Oregon respondents also had a higher
prevalence of noting schedule conflicts, such as whether
they have childcare available to attend research appoint-
ments (Oregon prevalence: 65%, Appalachian prevalence:
42%, PR = 1.54; 95% CI: 1.21, 1.95), and if their appoint-
ment times will interfere with their work schedule (PR =
1.63; 95% CI: 1.24, 2.14). Privacy of the research office (PR
= 1.32; 95% CI: 1.13, 1.53) and knowledge of why their in-
formation is being collected and what it will be used for
(PR = 1.46; 95% CI: 1.24, 1.73) were increased concerns
among Oregon compared to Appalachian respondents
(Table 3).
Compared to males (n = 137), female participants (n =
116) were more influenced to participate if they could
skip uncomfortable questions of parts of the study (PR =
1.34; 95% CI: 1.09, 1.65) and if their information would
be kept confidential (prevalence, females: 79%; males:
70%; PR = 1.15; 95% CI: 0.99, 1.32) (Table 4).
Compared to those who selected heroin (n = 90) as
their preferred drug of choice, respondents who selected
methamphetamine (n = 91) were more influenced by the
privacy of the research office (PR = 1.10; 95% CI: 0.99,
Table 2 Drug use history among rural PWUD in Kentucky, Ohio, and Oregon, April 2019–July 2019
Total study population (n = 255) Oregon (n = 79) Kentucky (n = 105) Ohio (n = 71)
n % n % n % n %
Ever injected drugs to get high
Yes 237 93 75 95 95 90 67 94
No 18 7 4 5 10 10 4 6
Drugs injected to get high in past 30 days
Methamphetamines 155 61 61 77 70 67 24 34
Heroin 144 57 42 53 48 46 54 76
Buprenorphine 47 18 5 6 33 31 9 13
Fentanyl 47 18 14 18 10 10 23 32
Painkillers 38 15 21 27 12 11 5 7
Cocaine/crack 21 8 11 14 6 6 4 6
Othera 11 4 10 13 0 0 1 1
Methadone 8 3 5 6 2 2 1 1
Prescription anxiety drugs 8 3 6 8 1 1 1 1
Gabapentin 1 1 1 1 0 0 0 0
Kratomb 1 1 1 1 0 0 - -
Clonidine 0 0 0 0 0 0 0 0
Synthetics 0 0 0 0 0 0 0 0
Drug of choice to get high
Methamphetamines 91 36 37 47 45 43 9 13
Heroin 90 35 33 42 24 23 33 47
Buprenorphine 14 6 0 0 12 11 2 3
Painkillers 13 5 2 3 11 11 0 0
Fentanyl 5 2 0 0 0 0 5 7
Otherc 3 1 3 4 0 0 0 0
Gabapentin 2 1 0 0 0 0 2 3
Methadone 1 1 0 0 1 1 0 0
Cocaine/crack 1 1 0 0 1 1 0 0
a“Other” responses included “cannabis” (n = 9), “pot, lsd, mushrooms, acid” (n = 1) and one response was missing (n = 1)
bKratom was not listed as a response option in the Ohio survey
c“Other” responses included “pot” (n = 2) and “lsd, doc, mushrooms” (n = 1)
Hetrick et al. Trials          (2021) 22:948 Page 6 of 17
1.20), knowing why their information is collected and
what it will be used for (prevalence, heroin: 59%, meth-
amphetamine: 74%; PR = 1.12; 95% CI: 1.00, 1.26), and
the confidentiality of their information (PR = 1.07; 95%
CI: 0.99, 1.16) (Table 5).
Patterns of motivations for research participation
Financial compensation was the primary motivator for par-
ticipation, followed by free diagnostic testing for infectious
diseases such as HCV and HIV, and believing in the mission
of the research and wanting to contribute (Fig. 2). “Knowing
a person on the research team and wanting to help them
out” was the least selected motivator for participation. Fifteen
participants selected “other” as a motivator for research par-
ticipation, while two participants left the response blank.
“Other” responses included “it’s convenient,” “people get
tired of watching their friends die,” “people might participate
because of their families,” and “some people want to come
and talk about getting off drugs and talk about resources.”
Compared to Appalachia respondents, Oregon re-
spondents had a higher prevalence of motivation to en-
roll in research if they believe in the mission of the
research and want to contribute (PR = 1.42; 95% CI:
1.18, 1.70) and to tell their story (PR = 1.37; 95% CI:
1.11, 1.70). The prevalence of noting feeling pressured
to participate by peers to share the financial incentive
(PR = 2.18; 95% CI: 1.56, 3.03) and knowing someone
on the research team and wanting to help them out (PR
= 2.12; 95% CI: 1.51, 2.99) was over two times greater
among Oregon respondents compared to Appalachian
respondents (Table 3).
Female participants were nearly twice as likely to re-
port being motivated to participate in a research study if
they knew someone on the research team (PR = 1.81;
95% CI: 1.09, 2.26) and were marginally more motivated
to participate if a financial incentive was offered (preva-
lence, females: 41%, males: 32%; PR = 1.10; 95% CI: 0.99,
1.23) (Table 4).
Fig. 1 Ranked influencing factors for participating in research among PWUD in rural communities, April 2019–July 2019
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Table 3 Influencing factors and motivators to research participation and barriers to retention: Oregon versus Appalachia PWUD











What the research study involves (e.g., survey, drug testing for research)c 71 8 111 65 – –
How much time is required 65 14 102 74 1.42* (1.21,
1.67)
How often they have to come in for visits 69 10 72 104 2.14* (1.75,
2.60)
How far they have to travel to participate (i.e., nearby vs. out of town)c 70 9 92 84 – –
Privacy of the research office 65 14 110 66 1.32* (1.13,
1.53)
Why their information is being collected and what it will be used for 65 14 99 77 1.46* (1.24,
1.73)
Whether their information will be kept confidentialc 72 7 118 58 – –
Whether the staff doing the research is friendly and trustworthyc 76 3 114 62 – –
Whether the research institution or university is respected 44 35 78 98 1.26 (0.97,
1.63)
Whether they can skip questions of parts of the study that make them
uncomfortable
60 19 88 88 1.52* (1.25,
1.84)
How much money they will receivec 70 9 113 63 – –
How much the project will benefit them overallc 70 9 88 88 – –
Whether their appointment times will interfere with their work schedule 46 33 63 113 1.63* (1.24,
2.14)
Whether they have childcare so that they can attend their appointments 51 28 74 102 1.54* (1.21,
1.95)
How their friends, family, or partner feels about them participating 49 30 64 112 1.71* (1.31,
2.21)
Motivations
Financial incentive (i.e., money or gift card given for participationc 79 0 134 42 – –
They believe in the mission of the research and want to contribute 61 18 96 80 1.42* (1.18,
1.70)
Their friends, family, or partner participates 65 14 97 79 1.49* (1.26,
1.77)
They want to tell their story 53 26 86 90 1.37* (1.11,
1.70)
They know someone on the research team and want to help them out 40 39 42 134 2.12* (1.51,
2.99)
They want to learn about the topic 51 28 79 97 1.44* (1.14,
1.81)
They would want to get free testing (for example, rapid tests for HIV
& Hepatitis C) if it was offered as part of the studyc
71 8 102 74 – –
They would want to be linked with resources and/or follow-up testing
if it was offered as part of the study
69 10 103 73 1.49* (1.28,
1.73)
They would want to try a new treatment if it was offered as part of
the study
68 11 105 71 1.44* (1.24,
1.68)
Their friends, family, or partner pressures them to participate so that
they can share the financial incentive
42 37 43 133 2.18* (1.56,
3.03)
Barriers
Not being able to get in touch with participants because their contact
information changedc
74 5 133 43 – –
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Respondents whose preferred drug of choice was
methamphetamine had a higher prevalence of being mo-
tivated to participate in research if they would receive
free diagnostic testing (PR = 1.08; 95% CI: 0.99, 1.18)
and linkage to resources and follow-up testing as part of
the study (PR = 1.09; 95% CI: 0.99, 1.21), compared to
respondents whose preferred drug of choice was heroin
(Table 5).
Patterns of anticipated barriers for retention in follow-up
research appointments
Losing contact with participants due to changed con-
tact information had the highest frequency of primary
responses among barriers to returning to follow-up
research appointments, followed by trouble obtaining
transportation and sharing false contact information
at their initial appointment (Fig. 3). The barrier with
the lowest number of ranked responses among re-
spondents was that their friends, family, or partner
may want them to stop participating. Twenty partici-
pants selected “other” as a barrier for research partici-
pation, while three participants left the response
blank. Their responses included, “being under the in-
fluence of drugs,” “if they did get clean this could be
a trigger to come into the office,” “it’s not that im-
portant to them,” “they may be high and forget,”
“people are scared to be tested for disease,” “people
aren’t in stable environments and move a lot,” “people
forget about the survey,” and “can’t force people to
come in, they make their own choices.”
Reporting conflicts in returning to follow-up appoint-
ments due to work, finding childcare, and transportation
were greatest among Oregon participants compared to
Appalachian participants (PR = 1.60; 95% CI: 1.26, 2.04,
PR = 1.60; 95% CI: 1.26, 2.01, and prevalence, Oregon:
81%, Appalachian: 70%; PR = 1.15; 95% CI: 0.99, 1.33, re-
spectively). Oregon participants also had a higher preva-
lence of reporting privacy and confidentiality concerns
(PR = 1.52; 95% CI: 1.22, 1.90) and becoming unreach-
able due to participation in a drug treatment program
(PR = 1.33; 95% CI: 1.09, 1.63). Barriers that did not dif-
fer between Appalachian and Oregon participants in-
cluded not being able to get in touch with participants
because they provided false contact information and they
may be afraid that the staff would judge them if they are
still using drugs (Table 3).
Female participants were more likely to identify
trouble finding transportation (PR = 1.12; 95% CI:
0.96, 1.30) and childcare (prevalence, females: 32%,
males: 21%; PR = 1.26; 95% CI: 0.98, 1.61) as chal-
lenges to returning to follow-up research appoint-
ments (Table 4).
Table 3 Influencing factors and motivators to research participation and barriers to retention: Oregon versus Appalachia PWUD
(Continued)










Not being able to get in touch with participants because they gave false
contact information when they started the study
46 33 100 76 1.02 (0.82,
1.29)
They may have trouble getting transportation for their appointments 64 15 124 52 1.15 (0.99,
1.33)
They may have trouble being able to show up at a specific appointment timec 72 7 108 68 – –
They may have trouble getting to their appointment because of their work
schedule
51 28 71 105 1.60* (1.26,
2.04)
They may have trouble finding childcare so that they can go to their
appointment
53 26 74 102 1.60* (1.26,
2.01)
They may have concerns about confidentiality and privacy 54 25 79 97 1.52* (1.22,
1.90)
They may be afraid that the staff would judge them if they are still using drugs 41 38 76 100 1.20 (0.92,
1.58)
They may have stopped using drugs and no longer think the study is relevant
to them
47 32 74 102 1.42* (1.10,
1.82)
They are in a drug treatment or recovery facility and are unable to be contacted
by research staff
55 24 92 84 1.33* (1.09,
1.63)
Their friends, family, or partner may want them to stop participating 28 51 49 127 1.27 (0.87,
1.86)
aKentucky and Ohio sites were combined to represent the referent group of “Appalachia”
bThe level of response for each survey item was dichotomized into “selected” or “not selected” to generate prevalence ratios
cOregon cell sizes for “not selected” were < 10; analysis not performed
* Significant at α =0.05 level
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Table 4 Influencing factors and motivators to research participation and barriers to retention among PWUD: gender differences








What the research study involves
(e.g., survey, drug testing for research)
100 37 81 35 0.98 (0.84, 1.15)
How much time is required 87 50 72 44 1.02 (0.85, 1.23)
How often they have to come in for visits 78 59 61 55 0.98 (0.78, 1.22)
How far they have to travel to participate
(i.e., nearby vs. out of town)
85 52 76 40 1.09 (0.90, 1.31)
Privacy of the research office 92 45 81 35 1.18 (0.70, 2.01)
Why their information is being collected and what it
will be used for
86 49 77 39 1.09 (0.91, 1.31)
Whether their information will be kept confidential 97 40 92 24 1.15 (0.99, 1.32)
Whether the staff doing the research is friendly and trustworthy 102 35 87 29 1.03 (0.89, 1.19)
Whether the research institution or university is respected 65 72 57 59 1.05 (0.81, 1.36)
Whether they can skip questions of parts of the study that
make them uncomfortable
70 67 77 39 1.34* (1.09, 1.65)
How much money they will receive 99 38 82 34 1.01 (0.87, 1.18)
How much the project will benefit them overall 81 56 77 39 1.14 (0.94, 1.38)
Whether their appointment times will interfere with
their work schedule
64 73 45 71 0.84 (0.63, 1.13)
Whether they have childcare so that they can attend
their appointments
66 71 59 57 1.07 (0.83, 1.38)
How their friends, family, or partner feels about them
participating
68 69 45 71 0.79 (0.60, 1.05)
Motivations
Financial incentive (i.e., money or gift card given for participation) 110 27 100 16 1.10 (0.99, 1.23)
They believe in the mission of the research and want to contribute 86 51 71 45 0.99 (0.81, 1.20)
Their friends, family, or partner participates 89 48 72 44 0.98 (0.82, 1.19)
They want to tell their story 77 60 62 54 0.96 (0.77, 1.21)
They know someone on the research team and want to
help them out
36 101 45 71 1.57* (1.09, 2.26)
They want to learn about the topic 73 64 56 60 0.94 (0.74, 1.20)
They would want to get free testing (for example, rapid
tests for HIV & Hepatitis C) if it was offered as part of the study
93 44 79 37 1.03 (0.87, 1.22)
They would want to be linked with resources and/or follow-up
testing if it was offered as part of the study
93 44 78 38 1.02 (0.86, 1.21)
They would want to try a new treatment if it was offered as
part of the study
93 44 79 37 1.03 (0.87, 1.22)
Their friends, family, or partner pressures them to participate so
that they can share the financial incentive
50 87 35 81 0.84 (0.59, 1.20)
Barriers
Not being able to get in touch with participants because
their contact information changed
111 26 94 22 1.03 (0.91, 1.16)
Not being able to get in touch with participants because they
gave false contact information when they started the study
76 61 69 47 1.11 (0.90, 1.37)
They may have trouble getting transportation for their appointments 97 40 89 27 1.12 (0.96, 1.30)
They may have trouble being able to show up at a specific
appointment time
94 43 85 31 1.09 (0.93, 1.28)
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Participant-prioritized barriers did not differ by drug
of choice (Table 5).
Discussion
We identified several themes of rural PWUD consider-
ations in deciding to participate and remain in research
studies. The primary influencing factor and motivator
for rural PWUD to participate in research is the amount
and presence of financial compensation. Economic and
social factors of the risk environment framework are de-
terminants of substance use [54] and promote a dispro-
portionate burden of substance use among people living
below the federal poverty threshold [1]. A lack of assist-
ance programs in areas where rural PWUD reside fur-
ther exacerbate the economic needs of this population
[55, 56]. The weight of financial compensation in our
findings is consistent with studies of rural Kentucky
PWUD populations and others that note receipt of fi-
nancial compensation as positively associated with re-
search participation and retention [24, 57, 58]. Lower
economic status is also associated with poorer study re-
tention; once enrolled in a longitudinal research study,
PWUD who live below the federal poverty line are more
likely to be lost to follow-up [59]. While financial com-
pensation can be used to offset economic needs of par-
ticipants and costs to participate such as travel and
childcare, additional research is required to ascertain ap-
propriate levels of financial compensation that do not
coerce study participation among PWUD [60].
Financial need is an undercurrent relevant to other
highly noted factors. Transportation was a major per-
ceived barrier to retention among all participants irre-
spective of participant region, gender, or preferred drug
use. Our findings align with previous studies that note
transportation, or distance, as a primary barrier to reten-
tion among rural community members [20]. Western
Oregon’s remote setting may increase transportation
challenges. Oregon participants were more likely to con-
sider factors and motivations for participation related to
transportation concerns such as the frequency of re-
search appointments and if their friend, family, or part-
ner participates. Strategies to alleviate transportation
challenges might include travel reimbursement, financial
incentive amounts that account for transportation cost,
or mobile or outreach models that bring the research to
the participant.
Although financial incentive is the primary motivation
for research participation among rural PWUD, our study
supports other findings that motivations are multi-
dimensional beyond monetary gains such as believing in
the mission of the research and seeking linkage to care
and other resources [57]. A lack of income paired with
scarce medical care in rural locations may also explain
the motivations noted by most rural PWUD to partici-
pate if linkage with resources and free testing are offered
as part of the study. In the U.S., cost or lack of reim-
bursement by insurance companies and uncertainty
about where to receive HIV care are reported as the pri-
mary barriers to HIV testing [61]. Due to a lack of
healthcare assistance programs and primary care pro-
viders in rural communities, and stigma in healthcare
settings, PWUD may prefer to access HCV and HIV
screening offered by research studies [8, 55].
Privacy, confidentiality, and interaction quality with
research staff are crucial influencing factors for PWUD
in deciding to participate in research, likely due to
stigma and the legal, employment, and inter-personal
relationship consequences of substance use. Oregon
Table 4 Influencing factors and motivators to research participation and barriers to retention among PWUD: gender differences
(Continued)







They may have trouble getting to their appointment because
of their work schedule
66 71 55 61 1.03 (0.79, 1.33)
They may have trouble finding childcare so that they can go to their
appointment
62 75 65 51 1.26 (0.98, 1.61)
They may have concerns about confidentiality and privacy 70 67 62 54 1.08 (0.86, 1.37)
They may be afraid that the staff would judge them if they
are still using drugs
60 77 56 60 1.15 (0.88, 1.50)
They may have stopped using drugs and no longer think the
study is relevant to them
63 74 57 59 1.11 (0.86, 1.44)
They are in a drug treatment or recovery facility and are unable
to be contacted by research staff
81 56 65 51 0.98 (0.79, 1.21)
Their friends, family, or partner may want them to stop participating 38 99 39 77 1.23 (0.85, 1.79)
aMale is the referent group
bThe level of response for each survey item was dichotomized into “selected” or “not selected” to generate prevalence ratios
*Significant at α = 0.05 level
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Table 5 Influencing factors and motivators to research participation and barriers to retention: drug of choice differences, heroin vs.
methamphetamine










What the research study involves
(e.g., survey, drug testing for research)
69 21 68 23 0.96 (0.86, 1.06)
How much time is required 67 23 58 33 0.91 (0.79, 1.03)
How often they have to come in for visits 57 33 56 35 0.90 (0.78, 1.05)
How far they have to travel to participate
(i.e., nearby vs. out of town)
58 32 67 24 1.01 (0.90, 1.13)
Privacy of the research office 58 32 73 18 1.10 (0.99, 1.20)
Why their information is being collected and
what it will be used for
53 37 67 24 1.12* (1.00, 1.26)
Whether their information will be kept confidential 63 27 80 11 1.07 (0.99, 1.16)
Whether the staff doing the research is friendly and trustworthyc 62 28 82 9 – –
Whether the research institution or university is respected 39 51 51 40 1.25* (1.08, 1.43)
Whether they can skip questions of parts of the study
that make them uncomfortable
51 39 61 30 1.04 (0.91, 1.19)
How much money they will receive 64 26 75 16 1.01 (0.92, 1.11)
How much the project will benefit them overall 58 32 68 23 0.93 (0.82, 1.05)
Whether their appointment times will interfere with
their work schedule
37 53 42 49 1.07 (0.88, 1.30)
Whether they have childcare so that they can attend
their appointments
41 49 51 40 1.08 (0.91, 1.28)
How their friends, family, or partner feels about
them participating
38 52 46 45 1.09 (0.90, 1.31)
Motivations
Financial incentive (i.e., money or gift card given
for participation
79 11 81 10 0.97 (0.91, 1.04)
They believe in the mission of the research and want
to contribute
61 29 64 27 0.93 (0.82, 1.06)
Their friends, family, or partner participates 63 27 67 24 0.93 (0.82, 1.04)
They want to tell their story 49 41 54 37 1.03 (0.88, 1.20)
They know someone on the research team and want to
help them out
27 63 37 54 1.00 (0.79, 1.28)
They want to learn about the topic 43 47 57 34 1.05 (0.90, 1.23)
They would want to get free testing (for example, rapid tests
for HIV & Hepatitis C) if it was offered as part of the study
55 35 78 13 1.08 (0.99, 1.18)
They would want to be linked with resources and/or
follow-up testing if it was offered as part of the study
55 35 73 18 1.09 (0.99, 1.21)
They would want to try a new treatment if it was offered as
part of the study
59 31 76 15 1.03 (0.93, 1.13)
Their friends, family, or partner pressures them to participate
so that they can share the financial incentive
34 56 32 59 0.88 (0.69, 1.13)
Barriers
Not being able to get in touch with participants because
their contact information changed
72 18 80 11 1.00 (0.93, 1.08)
Not being able to get in touch with participants because
they gave false contact information when they started the study
51 39 61 30 0.99 (0.87, 1.14)
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respondents were more likely to be motivated to partici-
pate in research if they knew someone on the research
staff. This finding may be related to the design of Ore-
gon’s concurrent study (i.e., the Oregon HIV/HCV and
Opioid Prevention and Engagement, or OR-HOPE)
which employs peer recovery support specialists as study
staff members [62]. While we found that most factors
among rural PWUD did not differ between males and
females, aligning with the findings of an analysis of 24
NIDA CTN trials [26], we found a notable difference in
the importance of privacy between genders. Females re-
ported an increased likelihood of indicating if their in-
formation would be kept confidential and whether they
can skip questions that make them uncomfortable as im-
portant for participation. Female PWUD participants
might be more concerned with privacy due to concerns
of their reputation [30] or losing custody of their chil-
dren if their drug use became publicly known [55] or
due to anticipated distress around certain topics related
to past trauma. Studies that recruit primarily rural, fe-
male PWUD should highlight confidentiality protections
when obtaining informed consent and reiterate these
protections throughout surveys, questionnaires, and
other data collection items to encourage participation
and improve comfort. In accordance with standards for
best practice in research with vulnerable populations
[63, 64], behavioral research studies can further support
female rural PWUD by providing the opportunity to opt
out of questions that make them uncomfortable.
Changing of participants’ contact information was a
primary perceived barrier to returning to follow-up ap-
pointments and did not differ between participant re-
gion, gender, or preferred drug use. Our findings align
with previous studies that note successfully contacting
participants as a barrier to retention among rural com-
munity members and PWUD [65]. Obtaining informa-
tion from participants about contact information of
others (family, friends, etc.) who know how to reach
them in case they cannot be contacted may improve re-
tention [20]. The challenge of losing contact with partic-
ipants may be alleviated by providing phone cards or
other forms of contact reimbursement.
Participants who reported methamphetamine as their
drug of choice to get high, as compared to those who se-
lected heroin, had a higher prevalence of considering fac-
tors central to privacy and confidentiality. While not all of
these factors met the threshold for statistical significance
(α = 0.05), the positive measure of association speaks to a
theme of distrust and privacy concerns present among
those who prefer methamphetamine use. These findings
align with a community-based study in Vancouver,
Canada, that found those who use methamphetamine re-
ported greater suspiciousness and paranoia compared to
those who use opioids [31]. Methamphetamine-associated
paranoia may magnify the general distrust of healthcare
systems where PWUD frequently experience stigma [66,
67] and may exacerbate skepticism about the transparency
of research which is already elevated among rural
Table 5 Influencing factors and motivators to research participation and barriers to retention: drug of choice differences, heroin vs.
methamphetamine (Continued)









They may have trouble getting transportation for their appointments 68 22 71 20 0.99 (0.89, 1.09)
They may have trouble being able to show up at a specific
appointment time
62 28 72 19 1.05 (0.95, 1.16)
They may have trouble getting to their appointment because
of their work schedule
44 46 46 45 1.04 (0.89, 1.21)
They may have trouble finding childcare so that they can go to their
appointment
47 43 49 42 0.94 (0.79, 1.12)
They may have concerns about confidentiality and privacy 43 47 60 31 1.09 (0.95, 1.26)
They may be afraid that the staff would judge them if they are
still using drugs
38 52 48 43 1.09 (0.91, 1.31)
They may have stopped using drugs and no longer think the
study is relevant to them
40 50 56 35 1.01 (0.86, 1.19)
They are in a drug treatment or recovery facility and are unable to be
contacted by research staff
49 41 60 31 1.09 (0.96, 1.25)
Their friends, family, or partner may want them to stop participating 29 61 28 63 0.94 (0.71, 1.24)
aHeroin as the preferred drug of choice is the referent group
bThe level of response for each survey item was dichotomized into “selected” or “not selected” to generate prevalence ratios
cCell sizes for “not selected” were < 10; analysis not performed
* Significant at α = 0.05 level
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residents [68]. Research enrolling people who use meth-
amphetamines in rural communities should tailor recruit-
ment and retention strategies to emphasize confidentiality
and privacy.
Our findings should be interpreted in light of several po-
tential limitations. First, though our sample was drawn
from U.S. rural communities in three states, findings may
not be generalizable to rural communities outside of Ap-
palachia and southwestern Oregon and may not be repre-
sentative of all PWUD in the study communities due to
our use of convenience sampling for data collection.
Demographic characteristics of our sample align with
those of previous studies of rural PWUD in the regions in-
cluded in our study (i.e., mostly male, white, low education
level, and age between 25 and 45 years [28, 69–72]); how-
ever, because county-level demographic information for
PWUD in the study areas are not publicly available, we
cannot fully assess the generalizability of our findings to
rural PWUD in these locations. Second, the numerous re-
sponse options provide crucial descriptive information on
improving clinical trial recruitment and retention in rural
areas but are likely correlated. Future work with large
population-based samples will be needed for testing mul-
tiple hypotheses of multilevel factors. Still, our study
found differences in factors for participation and retention
between geographic locations and types of preferred drug
use. The cross-sectional design of our study is a limitation
in regard to capturing the challenges of enrollment and
retention over time. We recommend that future longitu-
dinal clinical research studies explore enrolled partici-
pants’ influencing factors and motivations for
participation. Study staff should collect data on the rea-
sons rural PWUD participants miss follow-up
appointments among participants who are not lost to
follow-up. Another limitation is the difference in adminis-
tration methods between the three sites. The self-
administered survey among Ohio respondents likely con-
tributed to a lower selection of survey item responses. We
believe the lower selection of responses biased the preva-
lence ratio comparisons between Oregon and Appalachia
participants up and away from the null prevalence ratio
value (i.e., 1.0). However, previous studies have demon-
strated no difference in responses between interviewer-
and self-administered surveys [73, 74]. Based on our re-
sults, further research is needed to determine if a differ-
ence in modes of survey administration is present among
PWUD populations. A further limitation is that our re-
sults may differ by recency and duration of drug use; how-
ever, the need to reduce respondent burden precluded our
ability to examine these variables of interest. Finally, par-
ticipants were recruited in locations where epidemio-
logical studies had already been recruiting rural PWUD;
Fig. 2 Ranked motivators for joining a research study among PWUD in rural communities, April 2019–July 2019
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nearly two thirds of participants (64% overall, ranging
from 42% in Ohio to 75% in Kentucky) reported previ-
ously participating in a research study. Therefore, our re-
sults may not adequately capture the perspectives of rural
PWUD less familiar with or interested in research, which
may differ. However, because our participants are more fa-
miliar with research, the reported factors may have been
less hypothetical than with research naïve or adverse
PWUD.
Conclusions
Our findings contribute to the CTN’s focus on reaching
underserved populations, such as rural PWUD, by identifying
services such as testing, linkage to care, transportation, and
factors such as privacy of clinic location and confidentiality
of participant information that may enhance research partici-
pation and retention among this population. Research staff
can address barriers to returning to follow-up appointments
for rural PWUD by providing financial compensation, col-
lecting detailed contact information from participants, and
providing resources for transportation or by bringing the re-
search to the participants through mobile or street outreach.
Future longitudinal clinical research can leverage prominent
influencing factors, motivations, and barriers to enhance par-
ticipation and retention among rural PWUD.
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